Health Care & Life Sciences » Biotechnology | Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
66,083.50
36,140.10
29,102.80
73,740.30
88,205.80
96,967.80
Depreciation, Depletion & Amortization
2,099.30
1,569.30
1,918.60
3,086.00
3,469.00
4,996.80
Other Funds
-
-
149.60
149.60
-
13,711.50
Funds from Operations
13,814.30
31,227.50
25,694.70
62,025.60
62,495.80
78,259.60
Changes in Working Capital
1,566.80
1,303.10
13,255.80
529.40
713.10
4,709.40
Net Operating Cash Flow
15,381.10
29,924.40
12,438.90
62,555.10
63,208.90
73,550.20
Capital Expenditures
176.90
1,380.00
2,781.50
3,938.50
10,293.90
Purchase/Sale of Investments
11,059.90
34,432.20
53,042.60
19,210.40
18,537.20
Net Investing Cash Flow
9,236.80
35,812.20
54,824.10
16,271.90
27,831.10
Net Financing Cash Flow
52,691.90
72,461.70
84,351.70
7,786.90
95,690.20
Net Change in Cash
28,074.10
6,723.40
17,088.70
38,496.20
4,650.10
Free Cash Flow
15,558.00
31,304.40
15,220.40
66,493.50
73,502.80
Deferred Taxes & Investment Tax Credit
32.30
27.50
14.20
0.80
150.00
-
Other Sources
2,000.00
-
1,000.00
1,000.00
1,000.00
Change in Capital Stock
52,691.90
72,461.70
84,501.30
7,936.50
95,690.20
Exchange Rate Effect
0.10
1.70
-
-
-

About Inovio Pharmaceuticals

View Profile
Address
660 West Germantown Pike
Plymouth Meeting Pennsylvania 19462
United States
Employees -
Website http://www.inovio.com
Updated 07/08/2019
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.